Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roman Bronfenbrener

Dermatology Southampton, PA Medical Doctor

NPI 1134488638 CMS profile 1388655

1122 Street Rd Ste 204, Southampton, PA 18966

Open in the dashboard

General payments

$71,551

2,191 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roman Bronfenbrener of Southampton, PA is reported in the CMS Open Payments database as having received $71,551 across 2,191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,318 371
2024 General $14,690 429
2023 General $7,878 426
2022 General $14,381 440
2021 General $13,934 306
2020 General $3,240 86
2019 General $10,109 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roman Bronfenbrener
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Roman Bronfenbrener were reported at $7,318. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Roman Bronfenbrener Dermatology median Middle half National median
2019 $10,109 $454 $129–$1,240 $163
2020 $3,240 $235 $81–$756 $114
2021 $13,934 $377 $108–$1,108 $132
2022 $14,381 $514 $143–$1,391 $149
2023 $7,878 $607 $159–$1,674 $160
2024 $14,690 $751 $204–$1,903 $164
2025 $7,318 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $14,268 176 payments
  2. E.R. Squibb & Sons, L.L.C. $8,488 86 payments
  3. Dermira, Inc. $8,323 12 payments
  4. AbbVie, Inc. $6,590 363 payments
  5. Sun Pharmaceutical Industries Inc. $5,660 110 payments
  6. Janssen Biotech, Inc. $4,961 368 payments
  7. Mayne Pharma Inc. $2,065 129 payments
  8. UCB, Inc. $2,012 81 payments
  9. Novartis Pharmaceuticals Corporation $1,816 71 payments
  10. Incyte Corporation $1,517 101 payments
  11. Other $15,853 694 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $41,234 2,168 payments
  2. Consulting Fee $13,630 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,400 3 payments
  4. Honoraria $5,552 2 payments
  5. Travel and Lodging $1,147 5 payments
  6. Education $589 8 payments
Products named General payments · program years 2019–2025
  1. QBREXZA $8,289 10 payments
  2. EPSOLAY $6,616 19 payments
  3. AKLIEF $5,945 59 payments
  4. ORACEA $5,673 31 payments
  5. TREMFYA $4,733 259 payments
  6. HALOG $3,552 1 payment
  7. SKYRIZI $2,742 174 payments
  8. RINVOQ $2,307 132 payments
  9. VTAMA $1,461 64 payments
  10. OPZELURA $1,427 100 payments
  11. Other $31,721 1,785 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

8,606

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$1,230,956

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

8.8%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 201 $770,217
Tremfya Guselkumab Brand 11 $153,595
Otezla Apremilast Brand 13 $65,435
Ketoconazole Generic 3,057 $52,106
Betamethasone Dipropionate Generic 714 $32,785
Jublia Efinaconazole Brand 32 $30,333
Fluocinonide Generic 634 $25,536
Metronidazole Generic 303 $21,692
Tacrolimus Generic 107 $15,313
Triamcinolone Acetonide Generic 660 $8,206

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 130 billing codes

Paid by Medicare

$1,838,365

Of which drugs: $521,483

Medicare patients

1,657

Average age 77

Services billed

53,838

915 women, 742 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 46%
Ischemic heart disease 39%
Chronic kidney disease 24%
Osteoporosis 24%
Depression 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Cogenex amniotic membrane, per square centimeter Q4229 Office 12 170 $120,419
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 127 28,500 $37,569
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 228 1,380 $1,046
Injection, fluorouracil, 500 mg J9190 Office 13 22 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$1,368 11 —
SOTYKTU
$771 — —
SKYRIZI
$648 — —
Bimzelx
$591 — —
COSENTYX
$580 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

2,191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record